摘要
Abstract
OBJECTIVE:To systematically review the short-term efficacy and safety of paclitaxel combined with cisplatin in the treatment of advanced cervix cancer,and to provide evidence-based reference for clinical treatment. METHODS:Retrieved from CJFD,Wanfang database,VIP datebase,Cochrane library and EMBase,the randomized controlled trials(RCT)of paclitaxel+cisplatin(test group)versus surgery alone and/or combined with cisplatin(control group)in the treatment of advanced cervix can-cer were collected,and Meta-analysis was performed by using Rev Man 5.0 statistics software after extracting data and evaluating quality. RESULTS:A total of 9 RCTs were enrolled,involving 1 097 patients. Results of Meta-analysis showed total effective rate [OR=4.12,95%CI(2.91,5.83),P<0.001] in test group was significantly higher than control group,incidence of gastrointestinal re-actions [OR=0.22,95%CI(0.10,0.47),P<0.001] and incidence of alopecia [OR=0.48,95%CI(0.24,0.95),P=0.03] were signifi-cantly lower than control group;there were no significant differences in the incidence of myelosuppression [RR=1.02,95%CI (0.37,2.79),P=0.97] and incidence of allergic reaction[OR=1.87,95%CI(0.18,19.18),P=0.60] between 2 groups. CONCLU-SIONS:Paclitaxel combined with cisplatin has good short-term efficacy in the treatment of advanced cervix cancer,can reduce the incidence of adverse reactions and complications,with good safety. Due to the limit of research methodological quality,high quali-ty and large-scale RCTs are required for further validation of the conclusions.关键词
紫杉醇/顺铂/宫颈癌/近期疗效/并发症/安全性Key words
Paclitaxel/Cisplatin/Cervical cancer/Short-term efficacy/Complication/Safety分类
医药卫生
